Substantial Equivalence (SE) is evaluated through a documented comparison between the new aesthetic device and a legally marketed predicate device. The FDA assesses whether both devices have the same intended use and whether the new device has the same technological characteristics—or different characteristics that do not raise new questions of safety and effectiveness. The manufacturer must support the comparison with technical descriptions, performance testing, safety data, and clinical evidence when necessary.
SE does not mean the devices must be identical. It means the new device is sufficiently similar to a legally marketed predicate in intended use and safety/effectiveness profile, and that any technological differences are adequately justified.
How the FDA Frames the SE Decision
The 510(k) comparison is the foundation
For most devices seeking clearance through the 510(k) pathway, the manufacturer identifies one or more legally marketed predicate devices and compares the new device against them.
The submission must explain both the similarities and differences. A comparison table is commonly used to organize the analysis, but the FDA evaluates the underlying evidence—not the table alone.
Intended use must be the same
The FDA first considers whether the new device and predicate have the same intended use, including the clinical purpose and treatment goal.
For aesthetic equipment, this may involve indications such as hair reduction, treatment of pigmented lesions, vascular lesions, wrinkles, skin resurfacing, or tissue coagulation.
Differences in treatment claims, patient populations, anatomical sites, or disease conditions can affect the SE analysis. A device intended for a materially different clinical purpose may not be substantially equivalent to the selected predicate.
Technological characteristics are compared
The FDA evaluates the device’s key technological characteristics, including:
- Energy type, such as laser, intense pulsed light, radiofrequency, ultrasound, or other energy
- Wavelength or frequency
- Pulse width, duration, and repetition rate
- Fluence, power, energy, and delivery mode
- Spot size and treatment area
- Optical or energy-delivery systems
- Treatment tips and patient-contact materials
- Cooling systems
- Software and control functions
- Interlocks and other safety mechanisms
The comparison should address characteristics that could influence clinical performance or user and patient safety.
The Two Routes to Substantial Equivalence
Same intended use and same technological characteristics
The clearest route is demonstrating that the new device and predicate have the same intended use and essentially the same technological characteristics.
This does not require identical dimensions, components, or commercial design. The manufacturer must show that any differences do not meaningfully alter the device’s safety or effectiveness.
Same intended use with different technological characteristics
A new device may still be substantially equivalent when it uses different technology, provided the differences do not raise new questions of safety and effectiveness.
For example, a modified energy-delivery profile, updated cooling system, or different material may be acceptable if testing and analysis demonstrate that the change does not create an unresolved safety or performance concern.
The manufacturer must also provide evidence showing that the device performs at least as safely and effectively as the predicate for the relevant intended use.
What counts as a “new question”
A technological difference raises a new question when it creates a safety or effectiveness issue that is not adequately addressed by the predicate device’s established information or by applicable testing.
Examples may include substantially different tissue interaction, deeper energy penetration, higher delivered energy, a new mode of operation, or a material with different patient-contact risks.
The issue is not simply whether the technology is new. The key question is whether the difference changes the risk or performance profile in a way that requires additional evidence.
Evidence Used to Support the Comparison
Descriptive and comparative information
The submission should clearly describe the new device, its operating principles, components, accessories, software, and intended use.
A side-by-side comparison should identify each relevant difference rather than presenting only broad statements that the devices are similar.
Bench and performance testing
Performance testing may evaluate whether the device delivers energy as intended and within specified limits.
Depending on the technology, testing may address output accuracy, pulse characteristics, fluence, power, temperature, mechanical performance, tissue interaction models, durability, and operating limits.
Testing should use scientifically appropriate methods and acceptance criteria tied to the device’s intended use and identified risks.
Electrical, laser, and mechanical safety
Energy-based aesthetic devices generally require evaluation of applicable safety risks, including electrical hazards, unintended energy emission, overheating, mechanical hazards, and operator exposure.
Compliance with recognized consensus standards can support the submission, but standards compliance does not by itself establish substantial equivalence. The manufacturer must still connect the test results to the device’s safety and effectiveness.
Biocompatibility
Patient-contact components, such as treatment tips, applicators, covers, or microneedles, may require biocompatibility evaluation.
The assessment depends on the nature and duration of patient contact. Material information, chemical characterization, testing, and justification may be relevant when the new device uses different patient-contact materials.
Software and controls
Software that controls energy delivery, treatment parameters, user prompts, alarms, or safety interlocks must be evaluated according to its effect on device safety and performance.
The submission may need software documentation, verification and validation, cybersecurity information where applicable, and testing of fault conditions and protective controls.
Clinical evaluation
Clinical data are not automatically required for every 510(k) submission. They may become necessary when bench or nonclinical testing cannot adequately resolve the relevant safety or effectiveness questions.
Clinical evidence may also be important when the device has a new indication, substantially different energy behavior, a novel treatment method, or performance claims that cannot be supported through other accepted methods.
How the FDA Assesses Technological Differences
The difference must be tied to a potential risk
A manufacturer should not merely list a different wavelength, pulse width, material, or software function. It should explain how the difference could affect tissue response, treatment accuracy, adverse events, or user control.
This risk-based explanation helps determine whether additional testing is needed and whether the proposed evidence is sufficient.
The new device must be compared to the appropriate predicate
Predicate selection is a strategic and technical decision. The strongest predicate is generally one with a closely matching intended use, treatment site, energy behavior, risk profile, and performance claims.
A poorly matched predicate can create unnecessary questions about indications, technology, or clinical performance even when the device itself is well designed.
Equivalence is evaluated claim by claim
Clearance applies to the device and its described indications, not to every possible future use.
A device may be substantially equivalent for one treatment indication while requiring additional evidence for a different indication, anatomical site, patient population, or operating condition.
Understanding the Trade-offs
Similarity can simplify the submission
A close match to a well-characterized predicate may reduce uncertainty and allow established testing approaches to support the comparison.
It can also make the safety and effectiveness rationale easier for the FDA to review.
Similarity does not eliminate testing
Even a highly similar device requires adequate evidence. The manufacturer must establish that the finished device operates safely and performs as intended.
A marketing claim that a device is “similar to” an existing product is not a regulatory demonstration of SE.
New technology may require more evidence
Innovative energy profiles, new delivery mechanisms, deeper tissue effects, or substantially different treatment parameters can create additional review questions.
The appropriate response may include expanded bench testing, additional nonclinical testing, human factors work, or clinical data—not simply a broader comparison table.
A finding of NSE changes the regulatory pathway
If the FDA determines that the device is not substantially equivalent, the device cannot be cleared through that 510(k) submission.
Depending on the device’s classification and risk, the manufacturer may need to consider another pathway, such as De Novo classification for certain novel devices or PMA for devices requiring premarket approval. A finding of NSE does not automatically mean PMA is required.
Making the Right Choice for Your Submission
A reliable SE strategy begins before testing by defining the intended use, selecting the best predicate, identifying every meaningful difference, and mapping each difference to appropriate evidence.
- If your primary focus is predicate selection: Choose a legally marketed device with the closest match in intended use, treatment site, energy behavior, indications, and risk profile.
- If your primary focus is technical development: Document energy output, delivery characteristics, software functions, materials, cooling, and safety controls in a structured comparison.
- If your primary focus is evidence planning: Use bench, biocompatibility, software, electrical, laser, and other nonclinical testing to address each identified safety or performance risk.
- If your primary focus is a novel technology or indication: Determine early whether the differences raise new questions that may require clinical evidence or a different FDA pathway.
- If your primary focus is submission quality: Present a transparent comparison that explains not only how the devices differ, but why those differences do not compromise safety or effectiveness.
A strong SE submission turns device similarities and differences into a clear, evidence-based safety and effectiveness argument.
Summary Table:
| Aspect | Key Points |
|---|---|
| Intended Use | Must be the same as the predicate device. |
| Technological Characteristics | Compare energy type, wavelength, pulse width, fluence, cooling, software, etc. |
| Same Tech + Use | Straightforward SE if differences are minor and don't affect safety/effectiveness. |
| Different Tech | Acceptable if no new safety/effectiveness questions; require additional evidence. |
| Evidence Required | Descriptive, bench, safety, biocompatibility, software, and possibly clinical data. |
| Predicate Matching | Choose a close predicate for easier SE; poorly matched predicates create more review issues. |
Ready to bring your medical aesthetic device to market? Our experts at BELIS specialize in guiding manufacturers through the FDA's SE process. With our cutting-edge technology and regulatory expertise, we ensure your device meets all requirements efficiently. Contact us today to see how we can accelerate your approval pathway and enhance your product's success.